CXCR2 and neoplasm: These findings instructed the design of combination therapy, to block CSF1R signaling as well as CAFs: Combining CSF1R inhibitor with a CXCR2 antagonist blocked granulocyte infiltration and resulted in strong delay in tumor growth in models of lung carcinoma and melanoma (47).